| Name | Title | Contact Details |
|---|
POLYWOOD is a leader in the outdoor furniture industry, known for creating products from recycled plastic materials. Founded in 1990 and headquartered in Syracuse, Indiana, the company was the first to introduce outdoor furniture made from recycled plastics. POLYWOOD has expanded its operations with a second production and shipping facility in North Carolina. The companys mission emphasizes sustainability, focusing on both the production process and the materials used. POLYWOODs products, including the iconic Adirondack chair available in over 60 styles, are designed for durability and low maintenance. They are resistant to splintering, cracking, and rotting, and the company offers a 20-year lumber warranty. POLYWOOD also maintains a zero-waste mindset, recycling 99% of its waste stream. With over 1,550 employees, POLYWOOD operates a large manufacturing campus in Indiana. The company continues to innovate and expand its product lines, reinforcing its position as a pioneer in the outdoor furniture sector.
LFI specializes in the sale and service of contemporary furnishings to public, private, school, and academic libraries. By meeting the rapidly changing sociological and technological changes through design and product, LFI has become the Midwests leading library furnishing company.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
HPI redefines what is possible with self-funded health plans. As a third-party administrator, we partner with health plan brokers and employers to provide innovative self-funding strategies and customized plans tailored to each clients needs and population. Our solutions give employers greater cost transparency and control, while elevating the member experience.